Lobe Sciences (LOBEF)
OTHER OTC:LOBEF
LOBEF Stock Chart & Stats
$0.04
>-$0.01(-17.06%)
At close: 4:00 PM EST
$0.04
>-$0.01(-17.06%)
Day’s Range― - ―
52-Week Range$0.02 - $0.08
Previous CloseN/A
Volume171.00
Average Volume (3M)103.94K
Market Cap
$13.70M
Enterprise Value$10.73M
Total Cash (Recent Filing)$7.02M
Total Debt (Recent Filing)$295.68K
Price to Earnings (P/E)―
Beta0.03
Next Earnings
May 04, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding269,487,120
10 Day Avg. Volume62,263
30 Day Avg. Volume103,939
Financial Highlights & Ratios
PEG Ratio0.13
Price to Book (P/B)2.94
Price to Sales (P/S)0.00
P/FCF Ratio-4.89
Enterprise Value/Market Cap0.78
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-2.19
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low LeverageModest reported leverage reduces near-term refinancing pressure and interest burden, giving management flexibility to prioritize R&D and clinical programs. Lower debt improves survivability during long development cycles common in specialty drug makers.
Focused Therapeutic PipelineA dedicated R&D focus in psychedelic-derived therapeutics creates a clear strategic niche and potential for differentiated IP, clinical expertise, and partnerships. Specialization supports durable competitive positioning in a consolidated, high-barrier drug-development field.
Improving Cash-flow TrendAn improvement in free cash flow versus the prior year signals early operational progress and tighter cash discipline. If sustained, such a trend can reduce future external funding needs and extend runway for clinical milestones over the medium term.
Bears Say
Near-zero Revenue And Persistent LossesSubstantial trailing losses and effectively no revenue indicate the company is pre-commercial and not yet generating sustainable operating cash. Persistent negative EBIT and net losses mean long timelines to profitability and ongoing capital dependence.
Ongoing Cash BurnConsistent negative operating and free cash flow point to structural funding needs to sustain operations and trials. Continued cash burn increases dilution risk from future financings and constrains the company's ability to self-fund development programs.
Revenue Volatility And Weak Commercial TractionSharp revenue decline and reversion to near-zero highlight volatile or unsuccessful early commercialization efforts. This undermines predictability of cash flows and raises execution risk for scaling programs or converting R&D into repeatable revenue within the next 2–6 months.
Lobe Sciences News
LOBEF FAQ
What was Lobe Sciences’s price range in the past 12 months?
Lobe Sciences lowest stock price was $0.01 and its highest was $0.08 in the past 12 months.
What is Lobe Sciences’s market cap?
Lobe Sciences’s market cap is $13.70M.
When is Lobe Sciences’s upcoming earnings report date?
Lobe Sciences’s upcoming earnings report date is May 04, 2026 which is in 19 days.
How were Lobe Sciences’s earnings last quarter?
Currently, no data Available
Is Lobe Sciences overvalued?
According to Wall Street analysts Lobe Sciences’s price is currently Overvalued.
Does Lobe Sciences pay dividends?
Lobe Sciences does not currently pay dividends.
What is Lobe Sciences’s EPS estimate?
Lobe Sciences’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Lobe Sciences have?
Lobe Sciences has 269,487,120 shares outstanding.
What happened to Lobe Sciences’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Lobe Sciences?
Currently, no hedge funds are holding shares in LOBEF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Lobe Sciences
Lobe Sciences Ltd., a life sciences company, focuses on the research and development of psychedelic medicines. It develops psilocybin-based therapeutics in combination with N-acetylcysteine for the treatment of mild traumatic brain injuries and post-traumatic stress disorder, as well as devices for the efficient application of medications. The company was formerly known as Greenstar Biosciences Corp. and changed its name to Lobe Sciences Ltd. in November 2020. Lobe Sciences Ltd. is headquartered in Vancouver, Canada.
Technical Analysis
MediPharm Labs
―
PharmaCielo
―
Nextleaf Solutions
―
Avicanna
―
Greenway Greenhouse Cannabis Corp.
―
Ownership Overview
Options Prices
Currently, No data available
---